RxDoctor Payments Data

John Ferretti, DO

Internal Medicine · Erie, PANPI 1477518777

Payments from drug & device makers

$691in general payments, 2019–2025

Across 29 payments — averaging $23.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$179
  • Novartis$146
  • AbbVie$91
  • Johnson & Johnson$56
  • Boehringer Ingelheim$44
  • Daiichi Sankyo Inc.$42
  • plus $133 from 7 others

What the payments were for

  • Food & beverage$690100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$691 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$71,382
Medicare patients
477
Services billed
1,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban200$105,166
RexultiBrexpiprazole76$78,689
XareltoRivaroxaban115$61,058
Trelegy ElliptaFluticasone/Umeclidin/Vilanter63$47,542
MyrbetriqMirabegron113$46,134
JardianceEmpagliflozin61$44,136
NuedextaDextromethorphan Hbr/Quinidine25$36,778
TrulicityDulaglutide30$30,780
OzempicSemaglutide23$30,021
ZonisadeZonisamide16$27,812
EntrestoSacubitril/Valsartan29$16,814
TradjentaLinagliptin34$16,009
BriviactBrivaracetam15$15,781
ArexvyRsvpref3 Antigen/As01e/Pf43$12,851
Potassium Chloride290$12,721

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$56$61,058115 claims
Boehringer IngelheimJardiance, Tradjenta$44$60,14595 claims
Lilly USA, LLCTrulicity$36$30,78030 claims
Novo NordiskOzempic$179$30,02123 claims
NovartisEntresto$146$16,81429 claims
AstraZenecaFarxiga$15$8,29115 claims
Sumitomo Pharma America, Inc.Gemtesa$1$6,16314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →